News
Market Update
Eli Lilly's Foundayo Obesity Pill Lags Behind Novo's Wegovy in Early Launch
Suhaib
Executive summary
Eli Lilly's new oral weight-loss pill Foundayo recorded 3,707 U.S. prescriptions in its second week, significantly trailing Novo Nordisk's oral Wegovy, which had 18,410 prescriptions at the same point in its launch. The slow start has raised concerns about Lilly's ability to compete in the oral obesity drug market despite Foundayo's approval advantages and easier dosing.
What happened
Eli Lilly's Foundayo, approved on April 1 under an expedited FDA program, generated 3,707 prescriptions in its second week ending April 17, up from 1,390 in its debut week. This compares unfavorably to Novo Nordisk's oral Wegovy, which achieved 18,410 prescriptions in its second week after launching in January. Foundayo became available through LillyDirect on April 6, with broader retail pharmacy and telehealth access beginning April 9. The prescription data, sourced from IQVIA and cited by multiple Wall Street analysts, shows Foundayo's uptake at roughly 20% of oral Wegovy's first full week performance. Lilly has previously cautioned that early weekly prescription figures may not fully capture all pharmacy partners and should be interpreted over time rather than as complete counts.
Why it matters
The early prescription data matters because it represents Lilly's first major test in the oral obesity drug market, where Novo Nordisk gained first-mover advantage. Pills are viewed as the next frontier in weight-loss medicine due to greater convenience compared to injections. While Lilly's injectable Zepbound has successfully outperformed Novo's injectable Wegovy on efficacy in head-to-head trials, the slower pill launch suggests Lilly may struggle to replicate that success in the oral segment. Foundayo offers easier administration with fewer restrictions—no empty stomach requirement or 30-minute wait before eating—but this hasn't yet translated into strong initial demand. For investors, the launch performance is crucial because it tests whether Lilly can maintain momentum in the lucrative obesity treatment category, which has driven significant revenue growth. However, analysts note that factors like sampling programs and difficulty capturing telehealth prescriptions make early data less reliable, suggesting true performance won't be clear for two to three months.
Bigger picture
The oral obesity drug competition intensifies broader dynamics in the weight-loss pharmaceutical market. Novo Nordisk initially led the injectable obesity market but lost ground to Lilly's Zepbound, which demonstrated superior efficacy. Now Novo appears positioned to retain leadership in oral medications, with some analysts suggesting its pill may be the better product despite not being tested head-to-head against Foundayo. Clinical trial data shows Novo's oral Wegovy achieved greater weight loss in separate studies, though Foundayo uses a completely new active ingredient compared to Wegovy's semaglutide (the same compound in injectable Wegovy and Ozempic). The oral segment represents critical strategic territory because pills offer easier administration and potentially broader patient adoption. Novo's brand recognition advantage and three-month head start have proven meaningful in early prescription volumes. Beyond the Lilly-Novo rivalry, the obesity drug market continues expanding as pharmaceutical companies race to capture share in a category expected to generate tens of billions in annual revenue.
What to watch
Monitor Foundayo prescription trends over the next two to three months to assess whether uptake accelerates as awareness builds and distribution expands. Track whether Lilly's easier dosing protocol begins attracting patients who find Wegovy's empty-stomach requirement too restrictive. Watch for any head-to-head clinical trial announcements comparing the two pills directly on efficacy and tolerability. Pay attention to insurance coverage decisions and formulary placements, which could significantly impact prescription volumes. Observe whether Lilly expands its LillyDirect telehealth platform or announces partnerships to broaden access points. Monitor broader market commentary on oral versus injectable preferences among physicians and patients. Track supply chain updates, as manufacturing constraints have previously affected obesity drug availability. Finally, watch for any pricing adjustments or patient assistance programs that could influence competitive positioning.
This article was generated by Quantli AI using publicly available news sources.
